For the quarter ending 2025-09-30, TOVX had -$4,592K decrease in cash & cash equivalents over the period. -$4,338K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,361 | -17,382 |
| Stock-based compensation | 228 | 273 |
| Change in fair value of contingent consideration | 633 | 9,173 |
| Non-cash lease expense | 134 | 249 |
| Depreciation | 28 | 53 |
| Deferred research and development tax credit | -455 | -851 |
| Prepaid expenses and other current assets | -251 | -615 |
| Accounts payable | 161 | -301 |
| Accrued expenses | -784 | -602 |
| Accrued employee benefits | -9 | -427 |
| Operating lease liability | -145 | -268 |
| Net cash used in operating activities | -4,319 | -9,468 |
| Purchase of property and equipment | 19 | 16 |
| Net cash used in investing activities | -19 | -16 |
| Tax credit receivable | 41 | 1,798 |
| Proceeds from issuance of common stock | 0 | 6,690 |
| Proceeds from issuance of common stock for warrant exercises | 0 | 4 |
| Payment of loans payable | -2 | -67 |
| Proceeds from issuance atm offering, net of issuance costs | 279 | - |
| Payment of contingent consideration | -500 | - |
| Proceeds from long term debt | 34 | 1,458 |
| Net cash provided by financing activities | -148 | 9,883 |
| Effects of exchange rate changes on cash and cash equivalents | -106 | 62 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -4,592 | 461 |
| Cash and cash equivalents at beginning of period | 11,705 | - |
| Cash and cash equivalents at end of period | 7,574 | - |
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)